Completed PHASE2 INTERVENTIONAL 3-arm NCT04618211

Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema (RAPIDe-1)

A Phase II, Double-blind, Placebo-controlled, Randomized, Cross-over, Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema Due to C1-inhibitor Deficiency Type I and II

Sponsor: Pharvaris Netherlands B.V.

Conditions C1 Esterase Inhibitor Deficiency C1 Inhibitor Deficiency Hereditary Angioedema Hereditary Angioedema - Type 1 Hereditary Angioedema - Type 2 Hereditary Angioedema Attack Hereditary Angioedema Type I Hereditary Angioedema Type II Hereditary Angioedema Types I and II Hereditary Angioedema With C1 Esterase Inhibitor Deficiency

Interventions Deucrictibant Placebo

Updated 19 times since 2020 Last updated: Dec 2, 2025 Started: Feb 3, 2021 Primary completion: Sep 23, 2022 Completion: Mar 1, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04618211, this PHASE2 trial focuses on C1 Esterase Inhibitor Deficiency and C1 Inhibitor Deficiency and remains completed. Sponsored by Pharvaris Netherlands B.V., it has been updated 19 times since 2021, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

19 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE2
Sep 2025 — Jan 2026 [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jul 2023 — Jul 2024 [monthly]

Completed PHASE2

▶ Show 14 earlier versions

Jun 2023 — Jul 2023 [monthly]

Completed PHASE2
Apr 2023 — Jun 2023 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Sep 2022 — Apr 2023 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Mar 2022 — Sep 2022 [monthly]

Recruiting PHASE2
Jan 2022 — Mar 2022 [monthly]

Recruiting PHASE2
Nov 2021 — Jan 2022 [monthly]

Recruiting PHASE2
Oct 2021 — Nov 2021 [monthly]

Recruiting PHASE2
Sep 2021 — Oct 2021 [monthly]

Recruiting PHASE2
Jun 2021 — Sep 2021 [monthly]

Recruiting PHASE2
May 2021 — Jun 2021 [monthly]

Recruiting PHASE2
Apr 2021 — May 2021 [monthly]

Recruiting PHASE2
Mar 2021 — Apr 2021 [monthly]

Recruiting PHASE2
Jan 2021 — Mar 2021 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Dec 2020 — Jan 2021 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pharvaris Netherlands B.V.

Data source: Pharvaris Netherlands B.V.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amsterdam, Netherlands , Ashkelon, Israel , Barcelona, Spain , Berlin, Germany , Birmingham, United States , Brighton, United Kingdom , Brno, Czechia , Budapest, Hungary , Chevy Chase, United States , Dresden, Germany and 26 more locations